Journal
ACS BIOMATERIALS SCIENCE & ENGINEERING
Volume 8, Issue 9, Pages 3831-3841Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acsbiomaterials.2c00285
Keywords
tissue engineering; breast cancer; tumor modeling; biomaterials; microfluidics; drug testing
Categories
Funding
- Auburn University Research Initiative in Cancer (AURIC) Graduate Fellowship
- AU-CMB/NSF EPSCoR [NSF-EPS-1158862]
- Alabama EPSCoR Graduate Research Scholarship Program
- National Science Foundation [NSF-CBET-1743445]
- NIH [R15CA249788]
Ask authors/readers for more resources
This study successfully fabricated uniform microspheres encapsulating breast cancer cells using synthetic hybrid hydrogels and microfluidics technology, enabling quantification of cancer cell viability, metabolic activity, morphology, and stiffness over time. The research also demonstrated the translational potential of the microsphere platform in high-throughput drug screening.
Spheroidal cancer microtissues are highly advantageous for a wide range of biomedical applications, including high-throughput drug screening, multiplexed target validation, mechanistic investigation of tumor-extracellular matrix (ECM) interactions, among others. Current techniques for spheroidal tissue formation rely heavily on self-aggregation of single cancer cells and have substantial limitations in terms of cell-type-specific heterogeneities, uniformity, ease of production and handling, and most importantly, mimicking the complex native tumor microenvironmental conditions in simplistic models. These constraints can be overcome by using engineered tunable hydrogels that closely mimic the tumor ECM and elucidate pathologically relevant cell behavior, coupled with microfluidics-based high-throughput fabrication technologies to encapsulate cells and create cancer microtissues. In this study, we employ biosynthetic hybrid hydrogels composed of poly(ethylene glycol diacrylate) (PEGDA) covalently conjugated to natural protein (fibrinogen) (PEG-fibrinogen, PF) to create monodisperse microspheres encapsulating breast cancer cells for 3D culture and tumorigenic characterization. A previously developed droplet-based microfluidic system is used for rapid, facile, and reproducible fabrication of uniform cancer microspheres with either MCF7 or MDA-MB-231 (metastatic) breast cancer cells. Cancer cell-type-dependent variations in cell viability, metabolic activity, and 3D morphology, as well as microsphere stiffness, are quantified over time. Particularly, MCF7 cells grew as tight cellular clusters in the PF microspheres, characteristic of their epithelial morphology, while MDA-MB-231 cells displayed elongated and invasive morphology, characteristic of their mesenchymal and metastatic nature. Finally, the translational potential of the cancer microsphere platform toward high-throughput drug screening is also demonstrated. With high uniformity, scalability, and control over engineered microenvironments, the established cancer microsphere model can be potentially used for mechanistic studies, fabrication of modular cancer microtissues, and future drug-testing applications.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available